Section one: Contracting authority
one.1) Name and addresses
Medicines Discovery Catapult
Block 35, Mereside, Alderley Park
Cheshire
SK10 4TG
Contact
Mr Kieran McGowan
Kieran.McGowan@md.catapult.org.uk
Telephone
+44 1625708394
Country
United Kingdom
NUTS code
UKD62 - Cheshire East
Internet address(es)
Main address
Buyer's address
one.3) Communication
The procurement documents are available for unrestricted and full direct access, free of charge, at
https://procontract.due-north.com/RFx/RFxSummary?rfxId=7ff6f212-7298-eb11-810c-005056b64545
Additional information can be obtained from the above-mentioned address
Tenders or requests to participate must be submitted electronically via
https://procontract.due-north.com/RFx/RFxSummary?rfxId=7ff6f212-7298-eb11-810c-005056b64545
one.4) Type of the contracting authority
Other type
Research - Drug Discovery / Health
one.5) Main activity
Other activity
Research - Drug Discovery / Health
Section two: Object
two.1) Scope of the procurement
two.1.1) Title
MEP including Acoustic Consultant/BSL3 Laboratory – Full and complete service for the duration of the project life cycle Validation Centre
Reference number
DN537041
two.1.2) Main CPV code
- 45000000 - Construction work
two.1.3) Type of contract
Works
two.1.4) Short description
Medicines Discovery Catapult (MDC) is a national facility for collaborative R&D exploring and developing new approaches to the discovery and proof of well targeted medicines, diagnostics and biomarkers. Funded by Innovate UK, an agency of the UK government, MDC are an independent not-for-profit company bringing together a fragmented UK sector of industry, academia, charities, technologists, services, finance companies, SMEs and start-ups who together can turn good science into new, high value products. By sharing problems, rare expertise and assets we support the growth of this new community through a time of radical business and national change.
Capitalising on the success of the Lighthouse Lab to create a new BSL3 facility for innovative diagnostics, biomarkers and complex medicines and develop the UK’s onshore diagnostic capability and capacity and the associated supply chain. The project will create a national facility for testing and validation of new diagnostics, biomarkers and innovative therapeutics for disease.
The Validation Centre of Excellence will enable innovators to set up new companies with confidence, driving regional growth in high-value jobs and a sector of urgent national and global need. The Centre will build on the Lighthouse brand, creating a hub for new diagnostic and therapeutic validation.
MEP: Further information can be found at https://procontract.due-north.com/RFx/RFxSummary?rfxId=7ff6f212-7298-eb11-810c-005056b64545
two.1.6) Information about lots
This contract is divided into lots: No
two.2) Description
two.2.2) Additional CPV code(s)
- 71000000 - Architectural, construction, engineering and inspection services
two.2.3) Place of performance
NUTS codes
- UKD62 - Cheshire East
two.2.4) Description of the procurement
Medicines Discovery Catapult (MDC) is a national facility for collaborative R&D exploring and developing new approaches to the discovery and proof of well targeted medicines, diagnostics and biomarkers. Funded by Innovate UK, an agency of the UK government, MDC are an independent not-for-profit company bringing together a fragmented UK sector of industry, academia, charities, technologists, services, finance companies, SMEs and start-ups who together can turn good science into new, high value products. By sharing problems, rare expertise and assets we support the growth of this new community through a time of radical business and national change.
Capitalising on the success of the Lighthouse Lab to create a new BSL3 facility for innovative diagnostics, biomarkers and complex medicines and develop the UK’s onshore diagnostic capability and capacity and the associated supply chain. The project will create a national facility for testing and validation of new diagnostics, biomarkers and innovative therapeutics for disease.
The Validation Centre of Excellence will enable innovators to set up new companies with confidence, driving regional growth in high-value jobs and a sector of urgent national and global need. The Centre will build on the Lighthouse brand, creating a hub for new diagnostic and therapeutic validation.
MEP: Further information can be found at https://procontract.due-north.com/RFx/RFxSummary?rfxId=7ff6f212-7298-eb11-810c-005056b64545
two.2.5) Award criteria
Price is not the only award criterion and all criteria are stated only in the procurement documents
two.2.6) Estimated value
Value excluding VAT: £100,000
two.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Duration in months
12
This contract is subject to renewal
No
two.2.10) Information about variants
Variants will be accepted: No
two.2.11) Information about options
Options: No
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
Section four. Procedure
four.1) Description
four.1.1) Type of procedure
Open procedure
four.1.8) Information about the Government Procurement Agreement (GPA)
The procurement is covered by the Government Procurement Agreement: Yes
four.2) Administrative information
four.2.2) Time limit for receipt of tenders or requests to participate
Date
30 April 2021
Local time
12:00pm
four.2.4) Languages in which tenders or requests to participate may be submitted
English
four.2.6) Minimum time frame during which the tenderer must maintain the tender
Duration in months: 3 (from the date stated for receipt of tender)
four.2.7) Conditions for opening of tenders
Date
30 April 2021
Local time
12:05pm
Section six. Complementary information
six.1) Information about recurrence
This is a recurrent procurement: No
six.4) Procedures for review
six.4.1) Review body
Medicines Discovery Catapult
Block 35, Mereside, Alderley Park
Macclesfield
SK10 4TG
kieran.mcgowan@md.catapult.org.uk
Country
United Kingdom